Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun 11;10(6):e038863.
doi: 10.1136/bmjopen-2020-038863.

Variation in the estimated costs of pivotal clinical benefit trials supporting the US approval of new therapeutic agents, 2015-2017: a cross-sectional study

Thomas J Moore  1   2 , James Heyward  3 , Gerard Anderson  4 , G Caleb Alexander  5   6
Affiliations

Variation in the estimated costs of pivotal clinical benefit trials supporting the US approval of new therapeutic agents, 2015-2017: a cross-sectional study

Thomas J Moore et al. BMJ Open. .

Abstract

Objectives: Little is routinely disclosed about the costs of the pivotal clinical trials that provide the key scientific evidence of the treatment benefits of new therapeutic agents. We expand our earlier research to examine why the estimated costs may vary 100-fold.

Design: A cross-sectional study of the estimated costs of the pivotal clinical trials supporting the approval of 101 new therapeutic agents approved by the US Food and Drug Administration from 2015 to 2017.

Methods: We licensed a software tool used by the pharmaceutical industry to estimate the likely costs of clinical trials to be conducted by contract research organisations. For each trial we collected 52 study characteristics. Linear regression was used to assess the most important factors affecting costs.

Primary and secondary outcome measures: The mean and 95% CI of 225 pivotal clinical trials using varying assumptions. We also assessed median estimated costs per patient, per clinic visit and per drug.

Results: Measured as pivotal trials cost per approved drug, the 101 new molecular entities had an estimated median cost of US$48 million (IQR US$20 million-US$102 million). The 225 individual clinical trials had a median estimate of US$19 million (IQR US$12 million-US$33 million) per trial and US$41 413 (IQR, US$29 894-US$75 047) per patient. The largest single factor driving cost was the number of patients required to establish the treatment effects and varied from 4 patients to 8442. Next was the number of trial clinic visits, which ranged from 2 to 166. Our statistical model showed trial costs rose exponentially with these two variables (R2=0.696, F=257.9, p<0.01).

Conclusions: The estimated costs are modest for measuring the benefits of new therapeutic agents but rise exponentially as more patients and clinic visits are required to establish a drug effect.

Keywords: clinical pharmacology; clinical trials; epidemiology; medical law; public health.

PubMed Disclaimer

Conflict of interest statement

Competing interests: GCA is past Chair of FDA’s Peripheral and Central Nervous System Advisory Committee; serves as a paid advisor to IQVIA; is a paid consultant and holds equity in Monument Analytics, a healthcare consultancy whose clients include the life sciences industry as well as plaintiffs in opioid litigation and is a member of OptumRx’s National P&T Committee. This arrangement has been reviewed and approved by Johns Hopkins University in accordance with its conflict of interest policies.

Figures

Figure 1
Figure 1
Patient enrolment and estimated cost of pivotal trials. Kruskal-Wallis χ2=110.1, df=4, p value <0.01.
Figure 2
Figure 2
Patient visits versus estimated costs for pivotal trials. Adjusted R2=0.696, F=257.9 on 2 and 222 df, p<0.01. Variables log transformed.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Food and Drug Administration Food and Drug Administration Amendments Act (FDAAA) of 2007, 2007. Available: https://www.fda.gov/RegulatoryInformation/LawsEnforcedbyFDA/SignificantA... [Accessed 16 Apr 2018].
    1. International Committee of Medical Journal Editors Recommendations for the conduct, reporting, editing, and publication of scholarly work in medical journals. Available: http://www.icmje.org/ - PubMed
    1. Sertkaya A, Wong H-H, Jessup A, et al. . Key cost drivers of pharmaceutical clinical trials in the United States. Clin Trials 2016;13:117–26. 10.1177/1740774515625964 - DOI - PubMed
    1. Katz R. FDA: Evidentiary standards for drug development and approval. NeuroRx 2004;1:307–16. 10.1602/neurorx.1.3.307 - DOI - PMC - PubMed
    1. Moore TJ, Zhang H, Anderson G, et al. . Estimated costs of pivotal trials for novel therapeutic agents approved by the US Food and Drug Administration, 2015-2016. JAMA Intern Med 2018;178:1451–7. 10.1001/jamainternmed.2018.3931 - DOI - PMC - PubMed

Publication types